INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 42h ago
House PTR2h ago
SEC 13F2h ago
Robinhood Chain2h ago

Most active filers · 30d

  1. 01Kurtz George0B / 215S215 trades$52.62M
  2. 02FWFogarty Patrick W0B / 150S150 trades$600K
  3. 03SPSaba Capital Management, L.P.65B / 19S · 11 late84 trades$21.64M
  4. 04ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  5. 05AJAllaire Jeremy0B / 50S50 trades$4.26M
  6. 06Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  7. 07SJSheena Jonathan0B / 45S45 trades$3.01M
  8. 08SISarowitz Steven I2B / 34S36 trades$22.46M
  9. 09SLSpeiser Michael L0B / 35S35 trades$14.00M
  10. 10RARothblatt Martine A0B / 33S33 trades$5.50M

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 1732 insiders$917K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 179 insiders$893K
  4. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 168 insiders$42.58M
  5. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  6. SELLIBEXIBEX LtdNov 9 – Nov 167 insiders$3.36M
  7. SELLMGNIMAGNITE, INC.Nov 5 – Nov 127 insiders$2.27M
  8. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M

Form 4 transactions

72,558 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
CC
Cowan ChadChief Scientific Officer
IPSCCentury Therapeutics, Inc.
Tax withholding
F$1,603
1,611 sh
Jan 2, 2026Jan 6, 2026
Page 1536 of 1814
← PrevNext →
traded Jan 2, 2026
+4d
SEC Form 4

Evidence

5
RR
Ribeiro RamiroChief Medical Officer
EYPTEyePoint, Inc.
Option exercise
M—
19.7K sh
Jan 3, 2026Jan 6, 2026
traded Jan 3, 2026
+3dSEC Form 4

Evidence

5
FJ
Fitzpatrick JenniferChief Legal Officer
SIONSionna Therapeutics, Inc.
Grant or award
A—
103.1K sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC Form 4

Evidence

3
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$50K
4,796 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC Form 4

Evidence

3
SC
Spice Adam C.Chief Financial Officer
RKLBRocket Lab Corp
Option exercise · 10b5-1 plan
M—
731.3K sh
Jan 5, 2026Jan 6, 2026
traded Jan 5, 2026
+1dSEC Form 4

Evidence

3
KR
Kelleher Eric RobertSee Remarks
OKTAOkta, Inc.
Derivative conversion · 10b5-1 plan
C—
2,409 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC Form 4

Evidence

3
LM
Lin MarkEVP and CFO
SMTCSEMTECH CORP
Option exercise · 10b5-1 plan
M—
3,164 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC Form 4

Evidence

0
PA
Perez Daniel AntonioDirector, CEO & Co-Founder, 10% Owner
HNGEHinge Health, Inc.
Derivative conversion · 10b5-1 plan
C—
166.7K sh
Jan 5, 2026Jan 6, 2026
traded Jan 5, 2026
+1dSEC Form 4

Evidence

0
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$2,126
204 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC Form 4

Evidence

0
KR
Kelleher Eric RobertSee Remarks
OKTAOkta, Inc.
Derivative conversion · 10b5-1 plan
C—
2,409 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC Form 4

Evidence

0
SV
Singh VikasEVP & Chief Financial Officer
HCSGHEALTHCARE SERVICES GROUP INC
Option exercise · 10b5-1 plan
M—
3,980 sh
Jan 3, 2026Jan 6, 2026
traded Jan 3, 2026
+3dSEC Form 4

Evidence

0
GJ
Graham-Cumming JohnDirector
NETCloudflare, Inc.
Option exercise · 10b5-1 plan
M$113K
2,520 sh
Jan 5, 2026Jan 6, 2026
traded Jan 5, 2026
+1dSEC Form 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$4,293
412 sh
Jan 5, 2026Jan 6, 2026
traded Jan 5, 2026
+1dSEC Form 4

Evidence

0
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
4,796 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC Form 4

Evidence

0
SV
Singh VikasEVP & Chief Financial Officer
HCSGHEALTHCARE SERVICES GROUP INC
Grant or award · 10b5-1 plan
A—
17.8K sh
Jan 5, 2026Jan 6, 2026
traded Jan 5, 2026
+1dSEC Form 4

Evidence

0
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
204 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC Form 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$3,918
21 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC Form 4

Evidence

0
KR
Kelleher Eric RobertSee Remarks
OKTAOkta, Inc.
Option exercise · 10b5-1 plan
M—
2,409 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC Form 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
412 sh
Jan 5, 2026Jan 6, 2026
traded Jan 5, 2026
+1dSEC Form 4

Evidence

0
PA
Perez Daniel AntonioDirector, CEO & Co-Founder, 10% Owner
HNGEHinge Health, Inc.
Derivative conversion · 10b5-1 plan
C—
166.7K sh
Jan 5, 2026Jan 6, 2026
traded Jan 5, 2026
+1dSEC Form 4

Evidence

0
GJ
Graham-Cumming JohnDirector
NETCloudflare, Inc.
Option exercise · 10b5-1 plan
M—
2,520 sh
Jan 5, 2026Jan 6, 2026
traded Jan 5, 2026
+1dSEC Form 4

Evidence

0
KR
Kelleher Eric RobertSee Remarks
OKTAOkta, Inc.
Option exercise · 10b5-1 plan
M—
2,409 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC Form 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$19K
102 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC Form 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$17K
91 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC Form 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$8,850
46 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC Form 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$46K
4,432 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC Form 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
4,432 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC Form 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$39K
207 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC Form 4

Evidence

60
RV
Raghunathan VivekSVP, Engineering and Support
SNOWSnowflake Inc.
Open-market sale
SELL$2.60M
11.8K sh
Dec 31, 2025Jan 5, 2026
traded Dec 31, 2025
+5dSEC Form 4

Evidence

53
BS
Beri SanjayDirector, CEO and Chairman
NTSKNetskope Inc
Open-market sale
SELL$1.92M
108.6K sh
Dec 31, 2025Jan 5, 2026
traded Dec 31, 2025
+5dSEC Form 4

Evidence

43
BS
Beri SanjayDirector, CEO and Chairman
NTSKNetskope Inc
Open-market sale
SELL$5.85M
346.1K sh
Jan 2, 2026Jan 5, 2026
traded Jan 2, 2026
+3dSEC Form 4

Evidence

43
BS
Beri SanjayDirector, CEO and Chairman
NTSKNetskope Inc
Open-market sale
SELL$3.05M
175.7K sh
Jan 5, 2026Jan 5, 2026
traded Jan 5, 2026
+0dSEC Form 4

Evidence

36
PF
Pelayo FernandoEVP & Chief Accounting Officer
MCHBMechanics Bancorp
Grant or award
A—
65.0K sh
Sep 2, 2025Jan 5, 2026
traded Sep 2, 2025
+125dSEC Form 4

Evidence

36
PD
Pierce Christopher DEVP & Chief Operating Officer
MCHBMechanics Bancorp
Grant or award
A—
21.8K sh
Sep 26, 2025Jan 5, 2026
traded Sep 26, 2025
+101dSEC Form 4

Evidence

36
SC
Shrader Glenn CEVP & General Counsel
MCHBMechanics Bancorp
Grant or award
A—
19.5K sh
Sep 2, 2025Jan 5, 2026
traded Sep 2, 2025
+125dSEC Form 4

Evidence

36
KP
Kallingal Tony PEVP & Chief Banking Officer
MCHBMechanics Bancorp
Grant or award
A—
38.2K sh
Sep 2, 2025Jan 5, 2026
traded Sep 2, 2025
+125dSEC Form 4

Evidence

36
KP
Kallingal Tony PEVP & Chief Banking Officer
MCHBMechanics Bancorp
Grant or award
A—
20.0K sh
Sep 26, 2025Jan 5, 2026
traded Sep 26, 2025
+101dSEC Form 4

Evidence

35
JP
Jones Nina PDirector
SPGSIMON PROPERTY GROUP INC.
Open-market purchase
BUY$6,510
35 sh
Dec 31, 2025Jan 5, 2026
traded Dec 31, 2025
+5dSEC Form 4

Evidence

32
EW
Eager William WPresident, S&P Global Mobility
SPGIS&P Global Inc.
Option exercise
M$1.92M
3,670 sh
Dec 31, 2025Jan 5, 2026
traded Dec 31, 2025
+5dSEC Form 4

Evidence

31
RR
Renninger RobertChief Financial Officer
ATHALeonaBio, Inc.
Open-market sale
SELL$2,043
297 sh
Jan 2, 2026Jan 5, 2026
traded Jan 2, 2026
+3dSEC Form 4

Evidence